Clinical trials show similar safety outcomes including febrile convulsion rates for GSK’s and Merck’s measles-mumps-rubella (MMR) vaccines
Combined measles-mumps-rubella (MMR) vaccines produced by GSK (GSK-MMR) and Merck (Merck-MMR) have demonstrated effectiveness and an acceptable safety profile, as documented over decades of post-licensure use in various regions worldwide. In the United States, 2 doses of the MMR vaccine are recommen...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-01-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2023.2188852 |
| _version_ | 1797673148904112128 |
|---|---|
| author | Md Ahsan Habib Michael Povey Giacomo Casabona Tina Singh Remon Abu-Elyazeed |
| author_facet | Md Ahsan Habib Michael Povey Giacomo Casabona Tina Singh Remon Abu-Elyazeed |
| author_sort | Md Ahsan Habib |
| collection | DOAJ |
| description | Combined measles-mumps-rubella (MMR) vaccines produced by GSK (GSK-MMR) and Merck (Merck-MMR) have demonstrated effectiveness and an acceptable safety profile, as documented over decades of post-licensure use in various regions worldwide. In the United States, 2 doses of the MMR vaccine are recommended at the ages of 12–15 months and 4–6 years. All-cause febrile convulsions have the highest incidence at 12–18 months of age, when the first MMR vaccine dose is administered. Because febrile convulsions can also occur rarely after MMR vaccine administration, we reviewed safety data of the GSK-MMR compared to the Merck-MMR vaccine from 4 clinical trials that evaluated a first dose in 12–15-month-olds and 2 clinical trials that evaluated a second dose in ≥4-year-olds. Overall frequencies of febrile convulsions were ≤0.4% across studies and vaccine groups. The frequency of febrile convulsions occurring 7–10 days post-vaccination with the GSK-MMR vaccine (5.7/10,000) was generally consistent with previously published data. The other safety outcomes were similar between the GSK-MMR and Merck-MMR vaccines in both age groups. Hence, as recommended by the Advisory Committee on Immunization Practices, the GSK-MMR vaccine can also be used for routine immunization of children according to the current immunization schedule in the United States to prevent MMR. |
| first_indexed | 2024-03-11T21:40:18Z |
| format | Article |
| id | doaj.art-fabab714a90042afb694983316b19302 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:40:18Z |
| publishDate | 2023-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-fabab714a90042afb694983316b193022023-09-26T13:25:48ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2023-01-0119110.1080/21645515.2023.21888522188852Clinical trials show similar safety outcomes including febrile convulsion rates for GSK’s and Merck’s measles-mumps-rubella (MMR) vaccinesMd Ahsan Habib0Michael Povey1Giacomo Casabona2Tina Singh3Remon Abu-Elyazeed4GSKGSKGSKGSKGSKCombined measles-mumps-rubella (MMR) vaccines produced by GSK (GSK-MMR) and Merck (Merck-MMR) have demonstrated effectiveness and an acceptable safety profile, as documented over decades of post-licensure use in various regions worldwide. In the United States, 2 doses of the MMR vaccine are recommended at the ages of 12–15 months and 4–6 years. All-cause febrile convulsions have the highest incidence at 12–18 months of age, when the first MMR vaccine dose is administered. Because febrile convulsions can also occur rarely after MMR vaccine administration, we reviewed safety data of the GSK-MMR compared to the Merck-MMR vaccine from 4 clinical trials that evaluated a first dose in 12–15-month-olds and 2 clinical trials that evaluated a second dose in ≥4-year-olds. Overall frequencies of febrile convulsions were ≤0.4% across studies and vaccine groups. The frequency of febrile convulsions occurring 7–10 days post-vaccination with the GSK-MMR vaccine (5.7/10,000) was generally consistent with previously published data. The other safety outcomes were similar between the GSK-MMR and Merck-MMR vaccines in both age groups. Hence, as recommended by the Advisory Committee on Immunization Practices, the GSK-MMR vaccine can also be used for routine immunization of children according to the current immunization schedule in the United States to prevent MMR.http://dx.doi.org/10.1080/21645515.2023.2188852febrile convulsionmeasles-mumps-rubella vaccinemeningismmmrsafety |
| spellingShingle | Md Ahsan Habib Michael Povey Giacomo Casabona Tina Singh Remon Abu-Elyazeed Clinical trials show similar safety outcomes including febrile convulsion rates for GSK’s and Merck’s measles-mumps-rubella (MMR) vaccines Human Vaccines & Immunotherapeutics febrile convulsion measles-mumps-rubella vaccine meningism mmr safety |
| title | Clinical trials show similar safety outcomes including febrile convulsion rates for GSK’s and Merck’s measles-mumps-rubella (MMR) vaccines |
| title_full | Clinical trials show similar safety outcomes including febrile convulsion rates for GSK’s and Merck’s measles-mumps-rubella (MMR) vaccines |
| title_fullStr | Clinical trials show similar safety outcomes including febrile convulsion rates for GSK’s and Merck’s measles-mumps-rubella (MMR) vaccines |
| title_full_unstemmed | Clinical trials show similar safety outcomes including febrile convulsion rates for GSK’s and Merck’s measles-mumps-rubella (MMR) vaccines |
| title_short | Clinical trials show similar safety outcomes including febrile convulsion rates for GSK’s and Merck’s measles-mumps-rubella (MMR) vaccines |
| title_sort | clinical trials show similar safety outcomes including febrile convulsion rates for gsk s and merck s measles mumps rubella mmr vaccines |
| topic | febrile convulsion measles-mumps-rubella vaccine meningism mmr safety |
| url | http://dx.doi.org/10.1080/21645515.2023.2188852 |
| work_keys_str_mv | AT mdahsanhabib clinicaltrialsshowsimilarsafetyoutcomesincludingfebrileconvulsionratesforgsksandmercksmeaslesmumpsrubellammrvaccines AT michaelpovey clinicaltrialsshowsimilarsafetyoutcomesincludingfebrileconvulsionratesforgsksandmercksmeaslesmumpsrubellammrvaccines AT giacomocasabona clinicaltrialsshowsimilarsafetyoutcomesincludingfebrileconvulsionratesforgsksandmercksmeaslesmumpsrubellammrvaccines AT tinasingh clinicaltrialsshowsimilarsafetyoutcomesincludingfebrileconvulsionratesforgsksandmercksmeaslesmumpsrubellammrvaccines AT remonabuelyazeed clinicaltrialsshowsimilarsafetyoutcomesincludingfebrileconvulsionratesforgsksandmercksmeaslesmumpsrubellammrvaccines |